• Consensus Rating: Buy
  • Consensus Price Target: C$5.31
  • Forecasted Upside: 339.05 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
C$1.21
▲ +0.04 (3.42%)

This chart shows the closing price for IMV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IMV Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMV

Analyst Price Target is C$5.31
▲ +339.05% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for IMV in the last 3 months. The average price target is C$5.31, with a high forecast of C$0.00 and a low forecast of C$0.00. The average price target represents a 339.05% upside from the last price of C$1.21.

This chart shows the closing price for IMV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in IMV. This rating has held steady since February 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2022Echelon Wealth PartnersReiterated RatingBuy
5/13/2022HC WainwrightReiterated RatingBuyC$13.00
4/13/2022HC WainwrightReiterated RatingBuyC$13.00
2/25/2022HC WainwrightReiterated RatingBuyC$13.00
12/22/2021Raymond JamesReiterated RatingHoldC$1.75
11/12/2021National BanksharesLower Price TargetSector PerformC$4.25 ➝ C$2.50
11/11/2021HC WainwrightReiterated RatingBuyC$13.00
9/22/2021Cantor FitzgeraldInitiated CoverageBuyC$4.00
8/11/2021National Bank FinancialReiterated RatingSector Perform Market Weight
7/16/2021Raymond JamesLower Price TargetMarket PerformC$2.50
5/13/2021Raymond JamesReiterated RatingMarket PerformC$3.60
5/13/2021National Bank FinancialLower Price TargetSector Perform ➝ Sector PerformC$5.25 ➝ C$4.25
5/13/2021National BanksharesLower Price TargetSector PerformC$5.25 ➝ C$4.25
3/18/2021Leede Jones GabReiterated RatingSpeculative Buy
3/18/2021Raymond JamesReiterated RatingMarket PerformC$3.00
3/18/2021National BanksharesLower Price TargetSector PerformC$5.25
12/4/2020Raymond JamesReiterated RatingMarket PerformC$3.00
8/7/2020National Bank FinancialDowngradeOutperform ➝ Sector PerformC$5.00 ➝ C$7.00
5/22/2020Raymond JamesReiterated RatingMarket PerformC$3.00
4/1/2020National Bank FinancialLower Price TargetOutperformC$9.25 ➝ C$5.00
3/31/2020B. RileyDowngradeBuy ➝ Neutral
3/5/2020National Bank FinancialLower Price TargetC$10.50 ➝ C$9.25
11/26/2019OppenheimerSet Price TargetOutperformC$9.00
5/29/2019B. RileyReiterated RatingBuy
3/25/2019HC WainwrightReiterated RatingBuy
3/25/2019National Bank FinancialLower Price TargetOutperformC$11.00 ➝ C$10.50
3/5/2019National Bank FinancialLower Price TargetOutperformC$12.00 ➝ C$11.00
12/13/2018Echelon Wealth PartnersReiterated RatingSpeculative Buy
6/19/2018Dawson JamesReiterated RatingBuy
6/5/2018MackieBoost Price TargetC$8.70 ➝ C$10.40
6/4/2018National Bank FinancialBoost Price TargetOutperformC$9.60 ➝ C$12.00
5/10/2018National Bank FinancialBoost Price TargetOutperformC$3.00 ➝ C$9.60
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/26/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
IMV logo
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Read More

Today's Range

Now: C$1.21
Low: C$1.16
High: C$1.22

50 Day Range

MA: C$1.58
Low: C$1.17
High: C$1.91

52 Week Range

Now: C$1.21
Low: C$1.16
High: C$3.01

Volume

50,064 shs

Average Volume

48,621 shs

Market Capitalization

C$99.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of IMV?

The following sell-side analysts have issued research reports on IMV in the last twelve months: Cantor Fitzgerald, Echelon Wealth Partners, HC Wainwright, National Bank Financial, National Bankshares, Inc., and Raymond James.
View the latest analyst ratings for IMV.

What is the current price target for IMV?

0 Wall Street analysts have set twelve-month price targets for IMV in the last year. Their average twelve-month price target is C$5.31, suggesting a possible upside of 339.0%.
View the latest price targets for IMV.

What is the current consensus analyst rating for IMV?

IMV currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMV will outperform the market and that investors should add to their positions of IMV.
View the latest ratings for IMV.

How do I contact IMV's investor relations team?

IMV's physical mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company's listed phone number is +1-902-4921819. The official website for IMV is www.imvaccine.com. Learn More about contacing IMV investor relations.